New Delhi: A US-based pharmaceutical company has bagged the contract from President Donald Trump’s administration to produce drugs that are used to fight coronavirus.
Phlow Corp, which has bagged the $354-million contract, said it had making pharmaceutical ingredients which can be used to produce medicines to treat COVID-19 patients.
The US administration’s move is considered as a strategy to counter the country’s heavy dependence on import of such ingredients. particularly from China and India.
The four-year contract, with an additional $458 million included as potential options, will enable the company to meet the shortfall of such drugs.
Following the outbreak of COVID pandemic, the US President had contacted Prime Minister Narendra Modi seeking such medicines which India had obliged.